Non-functional Pancreatic Neuroendocrine Tumor

MONDO:0004334 Pathograph 7 pancreatic neuroendocrine tumor

Non-functional pancreatic neuroendocrine tumor is a well-differentiated pancreatic neuroendocrine tumor that lacks a hormone-related clinical syndrome. Presentation is therefore often silent or driven by tumor bulk, local invasion, metastatic disease, or incidental imaging detection rather than by insulin, gastrin, glucagon, VIP, or serotonin excess.

Ask OpenScientist

Ask a research question about Non-functional Pancreatic Neuroendocrine Tumor. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

4
Pathophys.
5
Phenotypes
7
Pathograph
3
Genes
6
Treatments
1
Trials
1
Deep Research
⚙

Pathophysiology

4
Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth
Neoplastic pancreatic neuroendocrine cells proliferate as a well-differentiated tumor in the pancreas. Because the tumor is non-functional, early disease may not cause a hormone hypersecretion syndrome and can remain clinically silent.
neuroendocrine cell link
cell population proliferation link ↑ INCREASED
pancreas link
Downstream
Mass Effect and Metastatic Presentation Continued growth can produce abdominal symptoms, biliary obstruction, and metastatic spread, especially to the liver.
Show evidence (2 references)
PMID:21252315 SUPPORT Human Clinical
"Nonfunctional PanNETs grow silently and patients often present with either an asymptomatic abdominal mass or symptoms of abdominal pain secondary to compression by a large tumor."
This directly supports silent growth and mass-effect presentation as a distinguishing feature of non-functional PanNETs.
PMID:40901227 SUPPORT Human Clinical
"Non-functioning PNETs are often asymptomatic and detected incidentally."
The case report abstract supports incidental or asymptomatic detection as a common non-functional presentation.
MEN1/DAXX/ATRX Chromatin Regulator Inactivation
Recurrent PanNET alterations include MEN1 and DAXX/ATRX chromatin-regulator inactivation, supporting disordered chromatin state and tumor suppressor loss in well-differentiated pancreatic neuroendocrine tumor cells.
MEN1 link DAXX link ATRX link
chromatin organization link ↕ DYSREGULATED
Downstream
Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth Chromatin-regulator inactivation contributes to neuroendocrine tumor formation and progression.
Show evidence (2 references)
PMID:21252315 SUPPORT Human Clinical
"The most frequently mutated genes specify proteins implicated in chromatin remodeling: 44% of the tumors had somatic inactivating mutations in MEN1, which encodes menin, a component of a histone methyltransferase complex,"
Human tumor sequencing supports MEN1 chromatin-regulator alteration as a major PanNET mechanism.
PMID:21252315 SUPPORT Human Clinical
"DAXX and ATRX were mutated in 17 and 12 PanNETs, respectively."
Human tumor sequencing supports DAXX/ATRX chromatin-regulator alteration as another major PanNET mechanism.
mTOR Pathway Activation
A subset of PanNETs has recurrent alterations in mTOR pathway components, including TSC2, supporting dysregulated TORC1 signaling and a therapeutic rationale for mTOR inhibition.
TSC2 link
TORC1 signaling link ↕ DYSREGULATED
Downstream
Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth mTOR pathway dysregulation can contribute to neuroendocrine tumor growth and progression.
Show evidence (1 reference)
PMID:21252315 SUPPORT Human Clinical
"We also found mutations in genes in the mTOR (mammalian target of rapamycin) pathway in 14% of the tumors, a finding that could potentially be used to stratify patients for treatment with mTOR inhibitors."
Human tumor sequencing supports mTOR pathway alteration as a distinct PanNET mechanism with therapeutic implications.
Mass Effect and Metastatic Presentation
Lack of an early hormone syndrome can delay recognition until tumor bulk, gastrointestinal symptoms, biliary obstruction, or metastasis is present.
pancreas link liver link
Show evidence (2 references)
PMID:40314740 SUPPORT Human Clinical
"Nonfunctional tumors were much more prevalent (77.5%), with functional tumors primarily being insulinomas (75.9%)."
The large surgical cohort supports the high prevalence of non-functional pNETs among resected pNETs.
PMID:40314740 SUPPORT Human Clinical
"Metastasis was observed in 39.4% of patients at the time of diagnosis, predominantly in the liver."
This supports liver-predominant metastatic presentation in clinically managed pNET cohorts.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Non-functional Pancreatic Neuroendocrine Tumor Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

5
Digestive 3
Pancreatic Mass Neoplasm of the pancreas (HP:0002894)
Show evidence (1 reference)
PMID:21252315 SUPPORT Human Clinical
"Nonfunctional PanNETs grow silently and patients often present with either an asymptomatic abdominal mass or symptoms of abdominal pain secondary to compression by a large tumor."
The quoted text directly supports asymptomatic abdominal mass presentation.
Hepatic Metastases Neoplasm of the liver (HP:0002896)
HPO lacks a specific hepatic-metastasis term; HP:0002896 is used as the closest available phenotype term.
Show evidence (1 reference)
PMID:40314740 SUPPORT Human Clinical
"Metastasis was observed in 39.4% of patients at the time of diagnosis, predominantly in the liver."
Cohort data support liver-predominant metastatic disease at diagnosis.
Jaundice Jaundice (HP:0000952)
Constitutional 1
Abdominal Pain Abdominal pain (HP:0002027)
Show evidence (1 reference)
PMID:21252315 SUPPORT Human Clinical
"Nonfunctional PanNETs grow silently and patients often present with either an asymptomatic abdominal mass or symptoms of abdominal pain secondary to compression by a large tumor."
This supports abdominal pain as a mass-effect symptom in non-functional PanNET.
Growth 1
Weight Loss Weight loss (HP:0001824)
🧬

Genetic Associations

3
MEN1 alterations (Recurrent somatic driver or inherited predisposition gene)
Show evidence (1 reference)
PMID:21252315 SUPPORT Human Clinical
"44% of the tumors had somatic inactivating mutations in MEN1, which encodes menin, a component of a histone methyltransferase complex"
This establishes MEN1 as the most frequent recurrent alteration in the cited PanNET sequencing cohort.
DAXX/ATRX alterations (Recurrent chromatin-remodeling alterations)
Show evidence (1 reference)
PMID:21252315 SUPPORT Human Clinical
"DAXX and ATRX were mutated in 17 and 12 PanNETs, respectively."
This supports DAXX/ATRX chromatin-remodeling alteration as a recurrent PanNET genetic feature.
VHL hereditary predisposition (Inherited predisposition syndrome gene)
Show evidence (1 reference)
DOI:10.3390/cancers16112075 SUPPORT Other
"Other inherited syndromes associated with PanNETs include MEN4, von Hippel–Lindau (VHL) syndrome, neurofibromatosis type 1 (NF1), and tuberous sclerosis complex (TSC)."
The hereditary-syndrome review supports VHL as a germline predisposition context for PanNETs, including the non-functional subtype scope.
💊

Treatments

6
Surgical resection for localized non-functional PanNET
Action: surgical resection MAXO:0000448
Surgical resection is the definitive local treatment when non-functional PanNET is resectable and patient/tumor risk assessment favors surgery.
Show evidence (2 references)
PMID:40901227 SUPPORT Human Clinical
"Surgical resection remains the most definitive treatment modality."
The subtype-focused case report and review supports resection as the most definitive treatment modality for non-functioning PNET.
PMID:40319207 SUPPORT Other
"parenchymal-sparing resection of appropriately located tumors, anatomic pancreatectomy and, in select cases, debulking of metastatic disease, particularly in the liver."
Review-level evidence supports individualized surgical decision-making for nonfunctioning tumors.
Lanreotide somatostatin analog therapy
Action: Pharmacotherapy NCIT:C15986
Agent: lanreotide ↗
Long-acting somatostatin analog therapy is an early systemic option for advanced, well-differentiated, nonfunctioning, SSTR-positive gastroenteropancreatic neuroendocrine tumors, including pancreatic primaries.
Show evidence (1 reference)
PMID:25014687 SUPPORT Human Clinical
"Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival"
The CLARINET randomized trial supports lanreotide as antiproliferative therapy for metastatic enteropancreatic NETs, including nonfunctioning pancreatic tumors.
Everolimus for progressive advanced pNET
Action: Pharmacotherapy NCIT:C15986
Agent: everolimus ↗
Everolimus targets mTOR signaling and is used for progressive advanced pancreatic neuroendocrine tumors.
Mechanism Target:
INHIBITS mTOR Pathway Activation — Everolimus inhibits mTOR signaling downstream of recurrent PanNET mTOR-pathway alterations.
Show evidence (1 reference)
PMID:21306238 SUPPORT Human Clinical
"Everolimus, as compared with placebo, significantly prolonged progression-free survival among patients with progressive advanced pancreatic neuroendocrine tumors and was associated with a low rate of severe adverse events."
Randomized trial evidence supports everolimus as mTOR-targeted therapy for progressive advanced pancreatic neuroendocrine tumors.
Sunitinib for advanced pancreatic neuroendocrine tumor
Action: Pharmacotherapy NCIT:C15986
Agent: sunitinib ↗
Sunitinib is an anti-angiogenic multi-kinase inhibitor option for advanced pancreatic neuroendocrine tumors.
Show evidence (1 reference)
PMID:21306237 SUPPORT Human Clinical
"Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors."
Randomized trial evidence supports sunitinib in advanced pancreatic neuroendocrine tumors.
Temozolomide and capecitabine chemotherapy
Action: chemotherapy MAXO:0000647
Agent: temozolomide ↗ capecitabine ↗
Capecitabine plus temozolomide is a systemic chemotherapy option for advanced pancreatic neuroendocrine tumors.
Show evidence (1 reference)
PMID:36260828 SUPPORT Human Clinical
"The combination of capecitabine/temozolomide was associated with a significant improvement in PFS compared with temozolomide alone in patients with advanced pancreatic NETs."
Randomized phase II evidence supports CAPTEM over temozolomide alone in advanced pancreatic NETs.
Peptide receptor radionuclide therapy
Action: radiation therapy MAXO:0000014
Peptide receptor radionuclide therapy targets somatostatin receptor-positive pancreatic neuroendocrine tumors and is being studied in the neoadjuvant setting for high-risk resectable non-functioning PanNET.
Show evidence (1 reference)
clinicaltrials:NCT04385992 SUPPORT Human Clinical
"The main aim of this study is to evaluate the safety and the efficacy of neoadjuvant PRRT with 177Lu-DOTATATE followed by surgical resection for resectable non-functioning PanNETs at high risk of recurrence."
The trial registry directly supports neoadjuvant PRRT as an investigated treatment strategy for resectable high-risk non-functioning PanNET.
🔬

Clinical Trials

1
NCT04385992 PHASE_II COMPLETED
Phase II single-arm study of neoadjuvant 177Lu-DOTATATE peptide receptor radionuclide therapy followed by surgery for resectable high-risk non-functioning PanNET.
Show evidence (2 references)
clinicaltrials:NCT04385992 SUPPORT Human Clinical
"The study is designed as a prospective phase II single-arm trial."
Registry text identifies the study design.
clinicaltrials:NCT04385992 SUPPORT Human Clinical
"Sample size estimation: 30 patients"
Registry text documents the planned sample size.
{ }

Source YAML

click to show 
name: Non-functional Pancreatic Neuroendocrine Tumor
creation_date: "2026-05-09T12:44:55Z"
updated_date: "2026-05-09T22:34:54Z"
synonyms:
- nonfunctional pancreatic neuroendocrine tumor
- non-functioning pancreatic neuroendocrine tumor
- nonfunctional pNET
- NF-pNET
- NF-PanNET
description: >-
  Non-functional pancreatic neuroendocrine tumor is a well-differentiated
  pancreatic neuroendocrine tumor that lacks a hormone-related clinical
  syndrome. Presentation is therefore often silent or driven by tumor bulk,
  local invasion, metastatic disease, or incidental imaging detection rather
  than by insulin, gastrin, glucagon, VIP, or serotonin excess.
categories:
- Gastrointestinal Cancer
- Endocrine Cancer
- Neuroendocrine Neoplasm
- Solid Tumor
parents:
- pancreatic neuroendocrine tumor
disease_term:
  preferred_term: non-functional pancreatic neuroendocrine tumor
  term:
    id: MONDO:0004334
    label: non-functional pancreatic neuroendocrine tumor
pathophysiology:
- name: Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth
  description: >-
    Neoplastic pancreatic neuroendocrine cells proliferate as a
    well-differentiated tumor in the pancreas. Because the tumor is
    non-functional, early disease may not cause a hormone hypersecretion
    syndrome and can remain clinically silent.
  cell_types:
  - preferred_term: neuroendocrine cell
    term:
      id: CL:0000165
      label: neuroendocrine cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  locations:
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nonfunctional PanNETs grow silently and patients often present with
      either an asymptomatic abdominal mass or symptoms of abdominal pain
      secondary to compression by a large tumor.
    explanation: >-
      This directly supports silent growth and mass-effect presentation as a
      distinguishing feature of non-functional PanNETs.
  - reference: PMID:40901227
    reference_title: "The Silent Presentation of a Non-functioning Pancreatic Neuroendocrine Tumor: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non-functioning PNETs are often asymptomatic and detected incidentally.
    explanation: >-
      The case report abstract supports incidental or asymptomatic detection as
      a common non-functional presentation.
  downstream:
  - target: Mass Effect and Metastatic Presentation
    description: >-
      Continued growth can produce abdominal symptoms, biliary obstruction, and
      metastatic spread, especially to the liver.
    causal_link_type: DIRECT
- name: MEN1/DAXX/ATRX Chromatin Regulator Inactivation
  description: >-
    Recurrent PanNET alterations include MEN1 and DAXX/ATRX
    chromatin-regulator inactivation, supporting disordered chromatin state and
    tumor suppressor loss in well-differentiated pancreatic neuroendocrine tumor
    cells.
  genes:
  - preferred_term: MEN1
    term:
      id: hgnc:7010
      label: MEN1
  - preferred_term: DAXX
    term:
      id: hgnc:2681
      label: DAXX
  - preferred_term: ATRX
    term:
      id: hgnc:886
      label: ATRX
  biological_processes:
  - preferred_term: chromatin organization
    modifier: DYSREGULATED
    term:
      id: GO:0006325
      label: chromatin organization
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequently mutated genes specify proteins implicated in chromatin
      remodeling: 44% of the tumors had somatic inactivating mutations in MEN1,
      which encodes menin, a component of a histone methyltransferase complex,
    explanation: >-
      Human tumor sequencing supports MEN1 chromatin-regulator alteration as a
      major PanNET mechanism.
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DAXX and ATRX were mutated in 17 and 12 PanNETs, respectively.
    explanation: >-
      Human tumor sequencing supports DAXX/ATRX chromatin-regulator alteration
      as another major PanNET mechanism.
  downstream:
  - target: Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth
    description: >-
      Chromatin-regulator inactivation contributes to neuroendocrine tumor
      formation and progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: mTOR Pathway Activation
  description: >-
    A subset of PanNETs has recurrent alterations in mTOR pathway components,
    including TSC2, supporting dysregulated TORC1 signaling and a therapeutic
    rationale for mTOR inhibition.
  genes:
  - preferred_term: TSC2
    term:
      id: hgnc:12363
      label: TSC2
  biological_processes:
  - preferred_term: TORC1 signaling
    modifier: DYSREGULATED
    term:
      id: GO:0038202
      label: TORC1 signaling
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also found mutations in genes in the mTOR (mammalian target of
      rapamycin) pathway in 14% of the tumors, a finding that could potentially
      be used to stratify patients for treatment with mTOR inhibitors.
    explanation: >-
      Human tumor sequencing supports mTOR pathway alteration as a distinct
      PanNET mechanism with therapeutic implications.
  downstream:
  - target: Silent Well-Differentiated Pancreatic Neuroendocrine Tumor Growth
    description: >-
      mTOR pathway dysregulation can contribute to neuroendocrine tumor growth
      and progression.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Mass Effect and Metastatic Presentation
  description: >-
    Lack of an early hormone syndrome can delay recognition until tumor bulk,
    gastrointestinal symptoms, biliary obstruction, or metastasis is present.
  locations:
  - preferred_term: pancreas
    term:
      id: UBERON:0001264
      label: pancreas
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:40314740
    reference_title: "Pancreatic Neuroendocrine Tumors-A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nonfunctional tumors were much more prevalent (77.5%), with functional
      tumors primarily being insulinomas (75.9%).
    explanation: >-
      The large surgical cohort supports the high prevalence of non-functional
      pNETs among resected pNETs.
  - reference: PMID:40314740
    reference_title: "Pancreatic Neuroendocrine Tumors-A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metastasis was observed in 39.4% of patients at the time of diagnosis,
      predominantly in the liver.
    explanation: >-
      This supports liver-predominant metastatic presentation in clinically
      managed pNET cohorts.
phenotypes:
- category: Neoplasm
  name: Pancreatic Mass
  description: >-
    A pancreatic mass may be detected incidentally or after local symptoms from
    growth or compression.
  phenotype_term:
    preferred_term: neoplasm of the pancreas
    term:
      id: HP:0002894
      label: Neoplasm of the pancreas
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nonfunctional PanNETs grow silently and patients often present with
      either an asymptomatic abdominal mass or symptoms of abdominal pain
      secondary to compression by a large tumor.
    explanation: >-
      The quoted text directly supports asymptomatic abdominal mass
      presentation.
- category: Gastrointestinal
  name: Abdominal Pain
  description: >-
    Abdominal pain can occur from pancreatic tumor bulk, compression, local
    invasion, or metastatic disease.
  phenotype_term:
    preferred_term: abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nonfunctional PanNETs grow silently and patients often present with
      either an asymptomatic abdominal mass or symptoms of abdominal pain
      secondary to compression by a large tumor.
    explanation: >-
      This supports abdominal pain as a mass-effect symptom in non-functional
      PanNET.
- category: Neoplasm
  name: Hepatic Metastases
  description: >-
    Liver metastases are a common site of spread in clinically recognized pNETs.
  notes: >-
    HPO lacks a specific hepatic-metastasis term; HP:0002896 is used as the
    closest available phenotype term.
  phenotype_term:
    preferred_term: hepatic metastases
    term:
      id: HP:0002896
      label: Neoplasm of the liver
  evidence:
  - reference: PMID:40314740
    reference_title: "Pancreatic Neuroendocrine Tumors-A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Metastasis was observed in 39.4% of patients at the time of diagnosis,
      predominantly in the liver.
    explanation: >-
      Cohort data support liver-predominant metastatic disease at diagnosis.
- category: Constitutional
  name: Weight Loss
  description: >-
    Weight loss may occur in clinically apparent or advanced disease, although
    it is not specific to the non-functional subtype.
  phenotype_term:
    preferred_term: weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Hepatic
  name: Jaundice
  description: >-
    Jaundice can occur when tumor location or spread obstructs the biliary tree.
  phenotype_term:
    preferred_term: jaundice
    term:
      id: HP:0000952
      label: Jaundice
genetic:
- name: MEN1 alterations
  association: Recurrent somatic driver or inherited predisposition gene
  relationship_type: SOMATIC_DRIVER
  presence: ABNORMAL
  frequency: FREQUENT
  gene_term:
    preferred_term: MEN1
    term:
      id: hgnc:7010
      label: MEN1
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      44% of the tumors had somatic inactivating mutations in MEN1, which
      encodes menin, a component of a histone methyltransferase complex
    explanation: >-
      This establishes MEN1 as the most frequent recurrent alteration in the
      cited PanNET sequencing cohort.
- name: DAXX/ATRX alterations
  association: Recurrent chromatin-remodeling alterations
  relationship_type: SOMATIC_DRIVER
  presence: ABNORMAL
  frequency: FREQUENT
  gene_term:
    preferred_term: DAXX
    term:
      id: hgnc:2681
      label: DAXX
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DAXX and ATRX were mutated in 17 and 12 PanNETs, respectively.
    explanation: >-
      This supports DAXX/ATRX chromatin-remodeling alteration as a recurrent
      PanNET genetic feature.
- name: VHL hereditary predisposition
  association: Inherited predisposition syndrome gene
  relationship_type: SUSCEPTIBILITY
  variant_origin: GERMLINE
  gene_term:
    preferred_term: VHL
    term:
      id: hgnc:12687
      label: VHL
  evidence:
  - reference: DOI:10.3390/cancers16112075
    reference_title: "Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors: A Systematic Review"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other inherited syndromes associated with PanNETs include MEN4, von Hippel–Lindau (VHL) syndrome, neurofibromatosis type 1 (NF1), and tuberous sclerosis complex (TSC)."
    explanation: >-
      The hereditary-syndrome review supports VHL as a germline predisposition
      context for PanNETs, including the non-functional subtype scope.
diagnosis:
- name: Cross-sectional and endoscopic imaging
  description: >-
    CT, MRI, and endoscopic ultrasound are key diagnostic modalities for
    non-functioning pNETs, especially because presentation can be incidental or
    clinically subtle.
  results: Pancreatic mass localization and tissue acquisition support diagnosis and grading.
  evidence:
  - reference: PMID:40314740
    reference_title: "Pancreatic Neuroendocrine Tumors-A Descriptive Study of the Presenting Features in a 20-Year Surgical Resection Cohort at a Tertiary Institution."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      computed tomography scans performed in 90.9% of patients. Endoscopic
      ultrasound (EUS) identified tumors in 98.1% of cases, with EUS-FNA
      showing a sensitivity of 82%.
    explanation: >-
      The large cohort supports CT and EUS/EUS-FNA as commonly used diagnostic
      modalities.
  - reference: PMID:40901227
    reference_title: "The Silent Presentation of a Non-functioning Pancreatic Neuroendocrine Tumor: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Imaging modalities like MRI, CT, and endoscopic ultrasound are key in
      diagnosis.
    explanation: >-
      This directly supports MRI, CT, and endoscopic ultrasound in the
      diagnostic workup.
- name: Somatostatin receptor PET imaging
  description: >-
    Somatostatin receptor PET imaging, such as 68Ga-DOTA PET, helps establish
    SSTR-positive disease status for staging and PRRT eligibility in
    non-functioning PanNET.
  results: Positive SSTR/DOTA PET supports suitability for somatostatin receptor-targeted therapy approaches.
  evidence:
  - reference: DOI:10.1093/bjs/znae178
    reference_title: "Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NEOLUPANET was a multicentre, single-arm, phase II trial of patients with sporadic, resectable or potentially resectable NF-PanNETs at high-risk of recurrence; those with positive 68Ga-labelled DOTA PET were eligible."
    explanation: >-
      The NF-PanNET PRRT trial required positive DOTA PET, supporting SSTR PET as
      the companion diagnostic for receptor-targeted therapy selection.
- name: Molecular testing of PanNET tissue
  diagnosis_term:
    preferred_term: genetic testing
    term:
      id: MAXO:0000127
      label: genetic testing
  description: >-
    Tumor molecular profiling can identify recurrent MEN1, DAXX/ATRX, and mTOR
    pathway alterations and may inform prognosis or targeted therapy selection.
  results: Somatic profiling can reveal chromatin-remodeling and mTOR-pathway alterations.
  evidence:
  - reference: PMID:21252315
    reference_title: "DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To explore the genetic basis of PanNETs, we determined the exomic
      sequences of 10 nonfamilial PanNETs and then screened the most commonly
      mutated genes in 58 additional PanNETs.
    explanation: >-
      This supports exome-based tumor profiling as a means to identify the
      recurrent genetic basis of PanNETs.
treatments:
- name: Surgical resection for localized non-functional PanNET
  description: >-
    Surgical resection is the definitive local treatment when non-functional
    PanNET is resectable and patient/tumor risk assessment favors surgery.
  treatment_term:
    preferred_term: surgical resection
    term:
      id: MAXO:0000448
      label: surgical resection
  evidence:
  - reference: PMID:40901227
    reference_title: "The Silent Presentation of a Non-functioning Pancreatic Neuroendocrine Tumor: A Case Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Surgical resection remains the most definitive treatment modality.
    explanation: >-
      The subtype-focused case report and review supports resection as the most
      definitive treatment modality for non-functioning PNET.
  - reference: PMID:40319207
    reference_title: "The Landmark Series: Surgical Management of Functioning and Non-Functioning Pancreatic Neuroendocrine Tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      parenchymal-sparing resection of appropriately located tumors, anatomic
      pancreatectomy and, in select cases, debulking of metastatic disease,
      particularly in the liver.
    explanation: >-
      Review-level evidence supports individualized surgical decision-making
      for nonfunctioning tumors.
- name: Lanreotide somatostatin analog therapy
  description: >-
    Long-acting somatostatin analog therapy is an early systemic option for
    advanced, well-differentiated, nonfunctioning, SSTR-positive
    gastroenteropancreatic neuroendocrine tumors, including pancreatic primaries.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lanreotide
      term:
        id: CHEBI:135901
        label: lanreotide
  evidence:
  - reference: PMID:25014687
    reference_title: Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival"
    explanation: >-
      The CLARINET randomized trial supports lanreotide as antiproliferative
      therapy for metastatic enteropancreatic NETs, including nonfunctioning
      pancreatic tumors.
- name: Everolimus for progressive advanced pNET
  description: >-
    Everolimus targets mTOR signaling and is used for progressive advanced
    pancreatic neuroendocrine tumors.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: everolimus
      term:
        id: CHEBI:68478
        label: everolimus
  target_mechanisms:
  - target: mTOR Pathway Activation
    treatment_effect: INHIBITS
    description: Everolimus inhibits mTOR signaling downstream of recurrent PanNET mTOR-pathway alterations.
  evidence:
  - reference: PMID:21306238
    reference_title: "Everolimus for advanced pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Everolimus, as compared with placebo, significantly prolonged
      progression-free survival among patients with progressive advanced
      pancreatic neuroendocrine tumors and was associated with a low rate of
      severe adverse events.
    explanation: >-
      Randomized trial evidence supports everolimus as mTOR-targeted therapy
      for progressive advanced pancreatic neuroendocrine tumors.
- name: Sunitinib for advanced pancreatic neuroendocrine tumor
  description: >-
    Sunitinib is an anti-angiogenic multi-kinase inhibitor option for advanced
    pancreatic neuroendocrine tumors.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sunitinib
      term:
        id: CHEBI:38940
        label: sunitinib
  evidence:
  - reference: PMID:21306237
    reference_title: "Sunitinib malate for the treatment of pancreatic neuroendocrine tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Continuous daily administration of sunitinib at a dose of 37.5 mg
      improved progression-free survival, overall survival, and the objective
      response rate as compared with placebo among patients with advanced
      pancreatic neuroendocrine tumors.
    explanation: >-
      Randomized trial evidence supports sunitinib in advanced pancreatic
      neuroendocrine tumors.
- name: Temozolomide and capecitabine chemotherapy
  description: >-
    Capecitabine plus temozolomide is a systemic chemotherapy option for
    advanced pancreatic neuroendocrine tumors.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
    therapeutic_agent:
    - preferred_term: temozolomide
      term:
        id: CHEBI:72564
        label: temozolomide
    - preferred_term: capecitabine
      term:
        id: CHEBI:31348
        label: capecitabine
  evidence:
  - reference: PMID:36260828
    reference_title: "Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The combination of capecitabine/temozolomide was associated with a
      significant improvement in PFS compared with temozolomide alone in
      patients with advanced pancreatic NETs.
    explanation: >-
      Randomized phase II evidence supports CAPTEM over temozolomide alone in
      advanced pancreatic NETs.
- name: Peptide receptor radionuclide therapy
  description: >-
    Peptide receptor radionuclide therapy targets somatostatin receptor-positive
    pancreatic neuroendocrine tumors and is being studied in the neoadjuvant
    setting for high-risk resectable non-functioning PanNET.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  evidence:
  - reference: clinicaltrials:NCT04385992
    reference_title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main aim of this study is to evaluate the safety and the efficacy of
      neoadjuvant PRRT with 177Lu-DOTATATE followed by surgical resection for
      resectable non-functioning PanNETs at high risk of recurrence.
    explanation: >-
      The trial registry directly supports neoadjuvant PRRT as an investigated
      treatment strategy for resectable high-risk non-functioning PanNET.
clinical_trials:
- name: NCT04385992
  status: COMPLETED
  phase: PHASE_II
  description: >-
    Phase II single-arm study of neoadjuvant 177Lu-DOTATATE peptide receptor
    radionuclide therapy followed by surgery for resectable high-risk
    non-functioning PanNET.
  evidence:
  - reference: clinicaltrials:NCT04385992
    reference_title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The study is designed as a prospective phase II single-arm trial.
    explanation: >-
      Registry text identifies the study design.
  - reference: clinicaltrials:NCT04385992
    reference_title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Followed by Surgery for Resectable Pancreatic Neuroendocrine Tumors
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sample size estimation: 30 patients
    explanation: >-
      Registry text documents the planned sample size.
notes: >-
  Falcon deep research completed on 2026-05-09. This subtype entry intentionally
  models the non-functional presentation and treatment implications rather than
  duplicating every mechanism already present on the parent pancreatic
  neuroendocrine tumor page.
datasets: []
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 41 citations 2026-05-09T09:03:43.913246

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Non-functional Pancreatic Neuroendocrine Tumor
  • MONDO ID: (if available)
  • Category:

Research Objectives

Please provide a comprehensive research report on Non-functional Pancreatic Neuroendocrine Tumor covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Non-functional Pancreatic Neuroendocrine Tumor (NF‑pNET / NF‑PanNET)

Target Disease

  • Disease name: Non-functional pancreatic neuroendocrine tumor (NF‑pNET; NF‑PanNET)
  • MONDO ID: MONDO:0004334 (disease-level identifier retrieved via Open Targets) (OpenTargets Search: pancreatic neuroendocrine tumor)
  • Category: Pancreatic neuroendocrine neoplasm; typically well-differentiated pancreatic neuroendocrine tumor (PanNET) subtype in WHO-aligned frameworks (saleh2024pancreaticneuroendocrinetumors pages 1-2, battistella2024recentdevelopmentsin pages 1-6)

Summary of key points (current understanding)

Non-functional PanNETs are pancreatic neuroendocrine tumors that do not present with a clinical hormone hypersecretion syndrome and therefore often present incidentally or late with mass effect and/or metastatic disease; they constitute a majority of pancreatic neuroendocrine neoplasms in contemporary series (often detected via high-quality cross-sectional imaging). Diagnosis relies on multimodal anatomical + functional imaging (especially SSTR PET) and pathology with Ki‑67 grading. Management is risk-stratified: active surveillance is accepted for carefully selected small (≤2 cm) low-risk lesions, while surgery is standard for higher-risk localized disease. For advanced disease, standard systemic options include somatostatin analogues (SSA), targeted therapy (everolimus, sunitinib), cytotoxic chemotherapy (CAPTEM), and peptide receptor radionuclide therapy (PRRT) for SSTR-positive tumors; sequencing is individualized by grade, tempo, tumor burden, and SSTR/FDG imaging phenotype (sulciner2023surgicalmanagementof pages 10-11, sulciner2023surgicalmanagementof pages 2-5, castillon2023seomgetneclinicalguidelines pages 9-10, melhorn2024treatmentsequencingin pages 2-3).

Disease MONDO ID Disease category Key synonyms / alternative names Classification / grading notes Citations
Non-functional pancreatic neuroendocrine tumor MONDO:0004334 Well-differentiated pancreatic neuroendocrine tumor (PanNET/PNET) subtype; pancreatic neuroendocrine neoplasm lacking a clinical hormone hypersecretion syndrome Non-functional pancreatic neuroendocrine tumor; nonfunctioning pancreatic neuroendocrine tumor; NF-pNET; NF-PanNET; nonfunctional PanNET; non-secreting pancreatic neuroendocrine tumor WHO 2022 framework distinguishes well-differentiated PanNET from poorly differentiated pancreatic neuroendocrine carcinoma (PanNEC); NF-pNET belongs to the well-differentiated PanNET group rather than PanNEC. Nonfunctional tumors comprise the majority of PanNENs / PanNETs in recent reviews. (OpenTargets Search: pancreatic neuroendocrine tumor, saleh2024pancreaticneuroendocrinetumors pages 1-2, battistella2024recentdevelopmentsin pages 1-6)
PanNET grading (applies to NF-pNET when well-differentiated) — Histologic grade within well-differentiated PanNET G1 PanNET; G2 PanNET; G3 well-differentiated PanNET Ki-67 / mitotic thresholds summarized in recent reviews: G1 = Ki-67 <3% and mitoses <2; G2 = Ki-67 3-20% and/or mitoses 2-20; G3 = Ki-67 >20% and/or mitoses >20. Current taxonomy separates well-differentiated G3 PanNET from poorly differentiated NEC. (sulciner2023surgicalmanagementof pages 1-2, saleh2024pancreaticneuroendocrinetumors pages 1-2)
PanNEC (important differential classification) — Poorly differentiated pancreatic neuroendocrine carcinoma Pancreatic NEC; poorly differentiated pancreatic neuroendocrine carcinoma Molecularly and pathologically distinct from PanNET; recent reviews note PanNEC commonly shows TP53 and RB1 alterations, whereas PanNET more often shows MEN1, DAXX, ATRX alterations. This distinction is critical because a high Ki-67 alone does not automatically indicate NEC if morphology is well differentiated. (battistella2024recentdevelopmentsin pages 16-20, saleh2024pancreaticneuroendocrinetumors pages 1-2, castillon2023seomgetneclinicalguidelines pages 2-4)
Hereditary / predisposition context relevant to NF-pNET — Often sporadic, but can occur in hereditary cancer syndromes MEN1-associated PanNET; VHL-associated PanNET; NF1-associated PanNET; TSC-associated PanNET Most PanNETs are sporadic, but ~10% are associated with germline syndromes in some reviews; a 2024 hereditary-syndrome review reports ~17% of PanNETs occur in inherited syndromes. VHL-associated PanNETs are described as almost exclusively nonfunctioning. (sulciner2023surgicalmanagementof pages 1-2, saleh2024pancreaticneuroendocrinetumors pages 1-2, papadopouloumarketou2024hereditarysyndromesassociated pages 1-3)

Table: This table summarizes standardized identifiers, common synonyms, and the core classification framework for non-functional pancreatic neuroendocrine tumor. It is useful for harmonizing disease labels in a knowledge base and for distinguishing well-differentiated NF-pNET from pancreatic NEC under WHO 2022-aligned grading concepts.

1. Disease information

1.1 Definition / overview

  • Pancreatic neuroendocrine tumors (PanNET/PNET) are rare pancreatic malignancies (≈2% of pancreatic neoplasms in a 2023 surgical review) and are classified clinically into functional versus non-functional based on hormone-related syndromes; nonfunctional tumors are a major fraction and are increasingly detected when small and asymptomatic (sulciner2023surgicalmanagementof pages 1-2).
  • A 2024 diagnostic review states that non-functioning PanNENs account for “the vast majority of PanNENs (60–90%)” and frequently produce non-specific symptoms leading to delayed detection; at diagnosis, “Overall, 12–74% of PanNENs have distant metastases, mainly hepatic.” (Expert Review of Gastroenterology & Hepatology; published May 2024; https://doi.org/10.1080/17474124.2024.2342837) (battistella2024recentdevelopmentsin pages 1-6).

1.2 Key identifiers

  • MONDO: MONDO:0004334 (OpenTargets Search: pancreatic neuroendocrine tumor)
  • Other identifiers (OMIM/Orphanet/ICD‑10/ICD‑11/MeSH): Not extracted from the available retrieved sources in this run; additional database queries would be required for a complete identifier crosswalk.

1.3 Synonyms / alternative names

Commonly used synonyms include: nonfunctioning pancreatic neuroendocrine tumor, nonfunctional PanNET, NF‑pNET, and NF‑PanNET (sulciner2023surgicalmanagementof pages 1-2, battistella2024recentdevelopmentsin pages 1-6).

1.4 Source type (patient-level vs aggregated)

The characterization above derives from aggregated sources (systematic reviews/guidelines and multi-center cohorts) rather than individual EHR records (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3, battistella2024recentdevelopmentsin pages 1-6, sulciner2023surgicalmanagementof pages 10-11).

2. Etiology

2.1 Disease causal factors (mechanistic)

NF‑PanNETs are neoplastic proliferations of pancreatic neuroendocrine cells characterized by recurrent alterations in chromatin regulators (MEN1/ATRX/DAXX) and signaling pathways including PI3K‑AKT‑mTOR; the biology is distinct from poorly differentiated pancreatic neuroendocrine carcinoma (PanNEC), which more often harbors TP53/RB1 alterations (saleh2024pancreaticneuroendocrinetumors pages 1-2, castillon2023seomgetneclinicalguidelines pages 2-4).

2.2 Risk factors

2.2.1 Genetic predisposition / hereditary syndromes

  • A 2023 review reports that ~10% of PanNETs arise in the context of inherited predisposition syndromes (MEN1, VHL, TSC1/TSC2, NF1) (Cancers; published Mar 2023; https://doi.org/10.3390/cancers15072006) (sulciner2023surgicalmanagementof pages 1-2).
  • A 2024 systematic review focused on hereditary syndromes reports “approximately 17% of PanNETs” develop in monogenic syndromes, especially MEN1, and also VHL, NF1, TSC, and MEN4 (Cancers; published May 2024; https://doi.org/10.3390/cancers16112075) (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).
  • The same review notes phenotype patterns important for the non-functional subtype: VHL-associated PanNETs are “almost exclusively nonfunctioning.” (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).
  • The review emphasizes early detection: genetic screening is recommended in childhood and diagnostic surveillance often begins in adolescence, including in asymptomatic carriers (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).

2.2.2 Non-genetic / metabolic risk associations

A 2026 review describes a bidirectional association between metabolic comorbidities (diabetes, obesity, metabolic syndrome) and gastroenteropancreatic neuroendocrine neoplasms, suggesting mechanistic links that may influence risk (conzo2026pancreaticneuroendocrinetumors pages 2-4).

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

Not identified in the retrieved evidence.

3. Phenotypes (clinical presentation)

3.1 Typical phenotype spectrum

  • NF‑PanNETs often present without hormone syndromes and can be discovered incidentally during imaging; nonspecific symptoms may include abdominal pain or weight loss or symptoms due to mass effect/obstruction and metastasis (battistella2024recentdevelopmentsin pages 1-6, sulciner2023surgicalmanagementof pages 2-5).
  • The presence of distant metastasis at diagnosis is reported across PanNEN series (wide range 12–74% reported, mainly hepatic) (battistella2024recentdevelopmentsin pages 1-6).

3.2 Phenotype characteristics (suggested HPO terms)

Because frequency-by-symptom data were not systematically extracted in the retrieved sources, the list below is intended for knowledge-base mapping and may require validation against additional primary cohorts: - Abdominal pain — HP:0002027 (often nonspecific) (battistella2024recentdevelopmentsin pages 1-6) - Unintentional weight loss — HP:0001824 (typical of malignancy; not quantified here) - Jaundice (if bile duct obstruction) — HP:0000952 (not quantified here) - Hepatic metastases — HP:0002897 (as a complication/metastatic phenotype; frequency range given for PanNENs broadly) (battistella2024recentdevelopmentsin pages 1-6)

3.3 Quality of life impact

Quality-of-life instruments are explicitly incorporated as outcomes in key trials of advanced disease (e.g., EORTC QLQ-C30 in NCT02358356; see Treatment section), indicating recognized QoL burden, but disease-specific QoL effect sizes were not extracted from mature trial publications in the current evidence set (NCT02358356 chunk 1).

4. Genetic / molecular information

4.1 Causal genes / recurrent drivers (somatic and germline)

NF‑PanNETs are not typically “single-gene” Mendelian disorders, but they show recurrent somatic driver alterations and may occur in germline syndromes.

4.1.1 Somatic driver landscape (recent quantitative synthesis)

A 2024 systematic review/meta-analysis of expanded sequencing datasets (14 datasets; 221 patients; 225 G1/G2 PanNETs) reported (Frontiers in Endocrinology; published May 2024; https://doi.org/10.3389/fendo.2024.1351624): - Tumor composition: 72.0% sporadic, 13.3% hereditary, 14.7% unknown germline status. - Most frequently altered gene: MEN1 altered in 42% overall (95/225); enriched in hereditary tumors (57%) versus sporadic (36%). - Other frequent alterations: DAXX 16% (37/225), ATRX 12% (27/225). - DAXX mutations were more frequent in MEN1-mutant tumors (p<0.05). - Importantly for non-functional tumors, the authors found non-functioning PanNETs had more recurrent variations in genes associated with PI3K, Wnt, NOTCH, and RTK–RAS pathways than functioning tumors (andersen2024welldifferentiatedg1and pages 1-2).

4.1.2 Germline predisposition genes/syndromes

Key syndromic genes include MEN1, VHL, NF1, TSC1/TSC2 (and less commonly CDKN1B/MEN4), with earlier onset and multifocality common in inherited cases (sulciner2023surgicalmanagementof pages 1-2, papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).

4.2 Epigenetic information

  • A 2023 review highlights that PanNETs have relatively low mutational burden and argues epigenetic regulators contribute to tumorigenesis; it states that drivers “MEN1, ATRX… and DAXX… are found in ~40% of sporadic PNETs” and reviews methylome-based clustering for prognosis (Endocrine Oncology; published 2023; https://doi.org/10.1530/eo-23-0003) (maluchenko2024molecularbasisof pages 17-18).
  • A 2024 review of signaling and epigenetics emphasizes that “epigenetic modifications encompass … DNA methylation, histone modifications, and non-coding RNAs (ncRNAs)” and notes “a lack of extensive research on epigenetic regulation in PNETs,” supporting ongoing research needs (International Journal of Molecular Sciences; published Jan 2024; https://doi.org/10.3390/ijms25021331) (saleh2024pancreaticneuroendocrinetumors pages 1-2).

4.3 Chromosomal / structural abnormalities

Not extracted from the retrieved evidence.

4.4 Suggested GO biological process terms (mechanism-linked)

Based on pathway emphasis in recent reviews and sequencing meta-analysis (to be refined for a knowledge base): - mTOR signaling — GO:0031929 (supported by mTOR-pathway alteration discussions) (battistella2024recentdevelopmentsin pages 16-20, saleh2024pancreaticneuroendocrinetumors pages 1-2) - Chromatin organization / remodeling — GO:0006325 / GO:0006338 (MEN1/ATRX/DAXX involvement) (andersen2024welldifferentiatedg1and pages 1-2, saleh2024pancreaticneuroendocrinetumors pages 1-2) - DNA damage response — GO:0006974 (ATRX functions and genome integrity context) (saleh2024pancreaticneuroendocrinetumors pages 1-2)

5. Mechanism / pathophysiology

5.1 Causal chain (high-level)

1) Initiating alterations: sporadic somatic mutations (MEN1, DAXX, ATRX) and pathway dysregulation (PI3K‑AKT‑mTOR and others) or germline predisposition (MEN1/VHL/NF1/TSC) (andersen2024welldifferentiatedg1and pages 1-2, saleh2024pancreaticneuroendocrinetumors pages 1-2, papadopouloumarketou2024hereditarysyndromesassociated pages 1-3). 2) Cellular consequences: altered chromatin regulation, proliferative signaling, and tumor heterogeneity; epigenetic remodeling and methylome alterations contribute to subtype differences and behavior (saleh2024pancreaticneuroendocrinetumors pages 1-2, maluchenko2024molecularbasisof pages 17-18). 3) Clinical manifestations: non-functional status leads to fewer early warning symptoms, increasing incidental detection or delayed presentation; progression leads to local mass effects and metastasis (often liver) (battistella2024recentdevelopmentsin pages 1-6, sulciner2023surgicalmanagementof pages 2-5).

5.2 Immune system involvement

A 2024 proteogenomic PanNET study (iScience) indicates aggressive subtypes can have immune/hypoxia signatures (study retrieved but not deeply extracted in evidence snippets here); thus immune microenvironment is a research focus but not yet a routine clinical biomarker in the provided evidence set (battistella2024recentdevelopmentsin pages 1-6).

5.3 Suggested cell-type (CL) terms

  • Pancreatic endocrine cell — CL:0000169 (tumor origin at islet/endocrine lineage level; general PanNET concept) (battistella2024recentdevelopmentsin pages 1-6)
  • Neuroendocrine cell — CL:0000165 (broad neuroendocrine lineage)

6. Anatomical structures affected

6.1 Primary / metastatic sites (UBERON suggestions)

  • Pancreas — UBERON:0001264 (primary site)
  • Liver — UBERON:0002107 (dominant metastatic site; hepatic metastases emphasized) (battistella2024recentdevelopmentsin pages 1-6)

6.2 Subcellular / compartment involvement (GO-CC suggestions)

  • Nucleus — GO:0005634 (chromatin regulators MEN1/ATRX/DAXX)
  • Chromatin — GO:0000785

7. Diagnostics (current applications and real-world implementations)

A multimodal strategy is standard. A 2024 diagnostic review summarizes: “PanNENs diagnostic work-up mainly relies on biochemical markers, pathological examination, and imaging evaluation,” including CT/MRI, SSTR PET and FDG PET, plus EUS with tissue procedures (battistella2024recentdevelopmentsin pages 1-6).

Modality Key performance / diagnostic yield Main use-cases in NF-PanNET Key limitations / caveats Citations
Contrast-enhanced CT Sensitivity ~82%; specificity 96% First-line anatomical imaging; localization of primary tumor; staging; assessment of arterial-phase hyperenhancement and metastatic spread May miss very small lesions; less sensitive than MRI for some liver metastases; limited grading information (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof media 0ba4a3b1, sulciner2023surgicalmanagementof media 7d24a64d, sulciner2023surgicalmanagementof media 210f90c9)
MRI Sensitivity 93%; specificity 88% High-sensitivity cross-sectional imaging; particularly useful for pancreas lesion characterization and liver metastasis detection Availability/cost; still limited for definitive grading; may require complementary functional imaging (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof media 0ba4a3b1, sulciner2023surgicalmanagementof media 7d24a64d, sulciner2023surgicalmanagementof media 210f90c9)
68Ga-DOTATATE PET/CT Sensitivity 93%; specificity 91%; detection reported ~95% for G1 and ~87.5% for G2 tumors, but only ~37.5% for G3 tumors Preferred somatostatin-receptor imaging for well-differentiated/SSTR-positive NF-PanNET; whole-body staging; occult lesion detection; therapy selection for SSA/PRRT Lower yield in higher-grade tumors; receptor-positive uptake is not entirely specific; should be integrated with morphology and grade (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof media 0ba4a3b1, sulciner2023surgicalmanagementof media 7d24a64d, sulciner2023surgicalmanagementof media 210f90c9, battistella2024recentdevelopmentsin pages 20-26, battistella2024recentdevelopmentsin pages 1-6)
18F-FDG PET/CT No sensitivity/specificity metric provided in the extracted evidence; recommended in combination with 68Ga-DOTA-peptide PET for comprehensive assessment Complements SSTR imaging; especially useful when tumor biology is more aggressive or higher grade is suspected Less emphasized for low-grade well-differentiated NF-PanNET than SSTR PET; evidence here is recommendation-based rather than metric-based (battistella2024recentdevelopmentsin pages 20-26, battistella2024recentdevelopmentsin pages 1-6)
EUS Mean sensitivity 75–97%; especially sensitive for lesions <2 cm Highest-sensitivity modality for small pancreatic lesions; local staging; nodal assessment; platform for tissue acquisition Operator dependence; invasive; may still require adjunct imaging for whole-body staging (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof media 0ba4a3b1, sulciner2023surgicalmanagementof media 7d24a64d, sulciner2023surgicalmanagementof media 210f90c9, battistella2024recentdevelopmentsin pages 20-26)
EUS-FNA In small lesions, tumor differentiation obtainable in 26.4% and Ki-67 in 20.1% of cases Cytologic confirmation when pathology will change management; preoperative diagnosis and preliminary grading Sampling error and intratumoral heterogeneity can underestimate grade; limited Ki-67 reliability in small samples (sulciner2023surgicalmanagementof pages 2-5, conzo2026pancreaticneuroendocrinetumors pages 5-7)
EUS-FNB (core biopsy) No pooled sensitivity/specificity provided in extracted evidence; reported to improve grading accuracy and Ki-67 reliability versus cytology alone Preferred over FNA when histologic architecture, biomarkers, or more reliable grading are needed for management decisions in NF-PanNET Discordance with resection specimen can persist; heterogeneity still limits accuracy; invasive procedure (conzo2026pancreaticneuroendocrinetumors pages 5-7)
Pathology / IHC Essential markers: synaptophysin, chromogranin A, Ki-67; Ki-67 central for WHO grade assignment Confirms neuroendocrine differentiation and provides grading; distinguishes well-differentiated PanNET from NEC in context of morphology and ancillary markers Biopsy-based Ki-67 may under- or overestimate true grade; interpretation depends on sample adequacy and heterogeneity (conzo2026pancreaticneuroendocrinetumors pages 5-7)
Multimodal imaging strategy Recommendation-based rather than a single metric: combined 68Ga-DOTA-peptide PET plus 18F-FDG PET is recommended for comprehensive assessment Integrates receptor status and tumor biology; supports staging, grading context, and treatment planning Requires access to advanced imaging and expert interpretation; cost and standardization remain issues (battistella2024recentdevelopmentsin pages 20-26, battistella2024recentdevelopmentsin pages 1-6)

Table: This table summarizes the main diagnostic tools used for non-functional pancreatic neuroendocrine tumors, including reported imaging performance metrics, tissue-based methods, and practical limitations. It is useful for comparing when each modality is most informative and how they are combined in real-world diagnostic workups.

7.1 Imaging: quantitative performance

A 2023 surgical management review reports the following diagnostic performance in pancreatic NETs (applied clinically to NF‑PanNET workups): - CT sensitivity ~82%, specificity 96%. - MRI sensitivity 93%, specificity 88%. - 68Ga‑DOTATATE PET/CT sensitivity 93%, specificity 91%; higher detection for G1/G2 than G3. - EUS mean sensitivity 75–97%, especially for lesions <2 cm. These data are reported in text and are captured in cropped evidence images (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof media 0ba4a3b1, sulciner2023surgicalmanagementof media 7d24a64d, sulciner2023surgicalmanagementof media 210f90c9).

7.2 Tissue diagnosis and pathology/IHC

  • Core principles: histologic confirmation and grading by Ki‑67/mitotic rate are central (sulciner2023surgicalmanagementof pages 1-2, conzo2026pancreaticneuroendocrinetumors pages 5-7).
  • Immunohistochemistry for synaptophysin, chromogranin A, and Ki‑67 is described as essential for confirming neuroendocrine differentiation and grading (conzo2026pancreaticneuroendocrinetumors pages 5-7).
  • Practical limitation in small tumors: EUS‑FNA yield may be low; one dataset reported tumor differentiation and Ki‑67 determination in only 26.4% and 20.1% of small lesions, respectively (sulciner2023surgicalmanagementof pages 2-5).

7.3 Functional imaging integration (68Ga + FDG)

A 2024 expert review states that “the use of [68Ga]Ga-DOTA-peptide PET and [18F]FDG PET scans is recommended for a comprehensive PanNEN assessment” (battistella2024recentdevelopmentsin pages 20-26).

7.4 Biomarkers

  • Conventional circulating markers (e.g., chromogranin A) have limited standalone utility in pNETs (conzo2026pancreaticneuroendocrinetumors pages 5-7).
  • Emerging biomarkers noted include molecular assays (e.g., NETest) and liquid biopsy approaches; however, reproducibility, standardization, and cost-effectiveness remain barriers (battistella2024recentdevelopmentsin pages 20-26).

7.5 Differential diagnosis

Hypervascular pancreatic lesions (e.g., solid serous cystadenoma) can mimic NF‑pNET on imaging, emphasizing need for multimodal assessment and/or tissue diagnosis when management would change (sulciner2023surgicalmanagementof pages 15-16).

8. Temporal development (onset and progression)

  • NF‑PanNETs are frequently discovered incidentally and can be indolent, but a meaningful fraction present with metastatic disease (liver predominant) (battistella2024recentdevelopmentsin pages 1-6).
  • Progression risk stratification relies heavily on tumor size, grade (Ki‑67), and nodal/metastatic status; Ki‑67 assessment variability and intratumoral heterogeneity are recognized issues in real-world grading from small biopsies (conzo2026pancreaticneuroendocrinetumors pages 13-13, conzo2026pancreaticneuroendocrinetumors pages 5-7).

Staging schema references (AJCC/ENETS) were not directly extracted in the retrieved evidence.

9. Inheritance and population

9.1 Epidemiology statistics

  • The 2024 diagnostic review reports an “annual incidence of less than 1 case per 100’000 inhabitants” for PanNENs and that they “account for less than 3% of all pancreatic tumors”; autopsy prevalence reported as 0.8–10% (battistella2024recentdevelopmentsin pages 1-6).
  • A 2026 review cites U.S. NET incidence rising to ~6.98 per 100,000 annually (NETs overall; not pancreas-specific) and attributes increases to improved diagnostics (conzo2026pancreaticneuroendocrinetumors pages 2-4).
  • Hereditary syndromes: MEN1 prevalence estimated 3–20 per 100,000, with MEN1 gene mutations causal; mutation carriers should undergo regular specialized screening from early adulthood in one 2024 review (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).

9.2 Inheritance patterns (for predisposition)

  • MEN1 is autosomal dominant; associated pancreatic NETs are often multifocal and earlier onset, motivating surveillance programs (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).
  • Other predisposition syndromes include VHL, NF1, and TSC (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).

Sex/ethnicity distributions were noted in a 2026 review (slight male predominance; higher prevalence in Caucasians) but without detailed pancreas-specific stratified estimates in the retrieved evidence (conzo2026pancreaticneuroendocrinetumors pages 10-11, conzo2026pancreaticneuroendocrinetumors pages 2-4).

10. Outcome / prognosis

10.1 Prognostic factors

Across cohorts and reviews, principal prognostic factors include grade (Ki‑67/mitotic), tumor size, nodal status, and metastatic burden. - Grade-specific survival differences: one 2023 review reports median overall survival approximately 12 years for grade 1 versus ~10 months for grade 3 pancreatic NET (sulciner2023surgicalmanagementof pages 1-2). - Recurrence risk factors after resection include tumor size >2 cm, symptomatic presentation, Ki‑67 >3%, and positive lymph nodes (sulciner2023surgicalmanagementof pages 2-5, sulciner2023surgicalmanagementof pages 1-2).

10.2 Prediction models

A 2023 systematic review of recurrence prediction models for resectable grade 1/2 sporadic NF‑pNETs (3583 patients across 14 studies) found c-statistics from 0.67 to 0.94, but noted high risk of bias in most model development studies; tumor grade, size, and lymph node positivity were the most frequent predictors (https://doi.org/10.3390/cancers15051525; published Feb 2023) (sulciner2023surgicalmanagementof pages 1-2).

11. Treatment (current standards, recent developments, and real-world implementation)

11.1 Localized disease: surveillance vs surgery

  • Active surveillance is increasingly used for carefully selected ≤2 cm asymptomatic NF‑PanNETs. A 2023 review summarizes guidance: ENETS recommends surveillance for nonfunctional PNETs ≤2 cm (low grade, asymptomatic, no suspicious radiographic features) with imaging every 6–12 months; NANETS supports observation for <1 cm and individualized decisions for 1–2 cm; NCCN supports observation ≤2 cm with stronger evidence for ≤1 cm (sulciner2023surgicalmanagementof pages 10-11).
  • Practical nuance: ENETS/ESMO allow surveillance but emphasize integration of growth kinetics, imaging risk features, and biopsy grade, and recognize Ki‑67 limitations in small samples (conzo2026pancreaticneuroendocrinetumors pages 13-13).

11.2 Systemic therapy for advanced / progressive disease

Treatment option Typical indication in NF-PanNET Key efficacy statistics Major adverse events / limitations Guideline / real-world notes
Active surveillance Selected asymptomatic, low-grade, localized tumors ≤2 cm, especially without suspicious imaging features or ductal dilation In a prospective international cohort of small NF-PNETs, 18.8% eventually underwent surgery, 2% progressed, and none developed metastases at last follow-up; some retrospective series found no disease-specific survival difference vs upfront surgery for small tumors (sulciner2023surgicalmanagementof pages 10-11, sulciner2023surgicalmanagementof pages 2-5) Risk of understaging; late recurrence/metastasis still reported in some series (nearly 8% in tumors ≤2 cm); requires reliable follow-up and careful risk stratification (sulciner2023surgicalmanagementof pages 10-11, conzo2026pancreaticneuroendocrinetumors pages 13-13) ENETS supports surveillance for selected asymptomatic ≤2 cm NF-pNETs; NANETS favors observation for <1 cm and individualized decisions for 1–2 cm; ESMO recommends individualized surveillance based on growth kinetics, imaging risk, and surgical risk (sulciner2023surgicalmanagementof pages 10-11, conzo2026pancreaticneuroendocrinetumors pages 13-13)
Surgery Localized resectable disease; symptomatic tumors; tumors >2 cm; lesions with duct dilation, growth, or other high-risk features Curative-intent standard for localized disease; no single pooled efficacy number in extracted evidence, but surgery remains the reference treatment for resectable tumors (sulciner2023surgicalmanagementof pages 2-5, conzo2026pancreaticneuroendocrinetumors pages 13-13) Pancreatic surgical morbidity can be substantial, reported up to 62% in some series, largely pancreatic fistula; extent of surgery must be balanced against tumor size/location and patient fitness (sulciner2023surgicalmanagementof pages 9-10) Still the cornerstone for cure; for small lesions, decision must integrate size, Ki-67, imaging, age/comorbidity, and patient preference (sulciner2023surgicalmanagementof pages 10-11, conzo2026pancreaticneuroendocrinetumors pages 13-13)
Somatostatin analogs (lanreotide / octreotide) SSTR-positive, well-differentiated, slowly progressive disease; often early-line systemic therapy CLARINET: lanreotide prolonged PFS, not reached vs 18.0 months; HR 0.47. CLARINET-FORTE pancreatic cohort: median PFS 5.6 months after dose intensification, suggesting limited benefit after progression (melhorn2024treatmentsequencingin pages 1-2, castillon2023seomgetneclinicalguidelines pages 9-10) Requires SSTR expression; limited benefit after progression when simply escalating dose interval; class toxicities/monitoring include hypersensitivity, cholelithiasis, and pancreatic exocrine insufficiency concerns (castillon2023seomgetneclinicalguidelines pages 9-10, melhorn2024treatmentsequencingin pages 2-3) Recommended first-line for slowly progressive enteropancreatic NET with low proliferative activity; also serves as backbone for sequencing and for SSTR-based strategies (melhorn2024treatmentsequencingin pages 2-3, melhorn2024treatmentsequencingin pages 1-2)
Everolimus Advanced progressive well/moderately differentiated NF-PanNET, including SSTR-negative or more rapidly growing disease RADIANT-3: median PFS 11.0 vs 4.6 months; HR 0.35. RADIANT-4: median PFS 11.0 vs 3.9 months; HR 0.48 (castillon2023seomgetneclinicalguidelines pages 9-10) Cytostatic rather than strongly cytoreductive; limited ORR in comparative sequencing context; adverse-event specifics not quantified in extracted evidence (castillon2023seomgetneclinicalguidelines pages 9-10, melhorn2024treatmentsequencingin pages 2-3) Guideline-endorsed targeted therapy; SEQTOR showed lower first-line response than chemotherapy (11% vs 30%) despite similar first-line PFS, informing sequencing discussions (castillon2023seomgetneclinicalguidelines pages 9-10)
Sunitinib Advanced progressive pancreatic NET, especially after or instead of SSA depending on disease tempo and biology Median PFS 11.4 vs 5.5 months; HR 0.42; p<0.001 (castillon2023seomgetneclinicalguidelines pages 9-10) TKI toxicity limits use in some patients; specific AE rates not reported in extracted evidence (castillon2023seomgetneclinicalguidelines pages 9-10) Approved for advanced progressive panNETs and remains a standard targeted option in sequencing algorithms (castillon2023seomgetneclinicalguidelines pages 9-10, melhorn2024treatmentsequencingin pages 2-3, melhorn2024treatmentsequencingin pages 1-2)
CAPTEM (capecitabine + temozolomide) Progressive advanced pancreatic NET, especially when tumor shrinkage is desired or in more proliferative disease E2211: PFS 22.7 vs 14.4 months vs temozolomide alone; HR 0.58; p=0.022; no OS benefit. SEQTOR: first-line response rate 30% vs 11% with everolimus, but similar first-line PFS 21.5 vs 23.6 months (castillon2023seomgetneclinicalguidelines pages 9-10) Chemotherapy toxicity and myelosuppression are practical concerns, though detailed AE rates were not extracted; evidence mainly from advanced disease rather than small localized NF-PNETs (castillon2023seomgetneclinicalguidelines pages 9-10) Often preferred when a higher objective response is needed; a key comparator in modern sequencing discussions against targeted therapy (castillon2023seomgetneclinicalguidelines pages 9-10, melhorn2024treatmentsequencingin pages 2-3)
PRRT (177Lu-DOTATATE) SSTR-positive well-differentiated advanced disease; increasingly considered earlier in selected patients; also under study neoadjuvantly in high-risk resectable NF-PanNET NETTER-1: HR for progression/death 0.21; median PFS not reached vs 8.4 months. NETTER-2: median PFS 22.8 vs 8.5 months; ORR 43% vs 9.3%. Long-term hematologic toxicity (MDS/leukemia) ~3–4% (melhorn2024treatmentsequencingin pages 2-3) Requires SSTR-positive disease and specialized centers; delayed hematologic toxicity is an important limitation (melhorn2024treatmentsequencingin pages 2-3) ESMO places PRRT later in pancreatic NET sequence after approved systemic options; ENETS allows rechallenge in selected patients. NeoLuPaNET (NCT04385992) tested neoadjuvant PRRT before surgery in high-risk resectable non-functioning PanNET, 31 enrolled, 4 cycles of 7,400 MBq every 6–8 weeks (melhorn2024treatmentsequencingin pages 2-3, NCT04385992 chunk 1)
PRRT + CAPTEM (investigational combination) Advanced unresectable low/intermediate-grade pNET in trial setting CONTROL NETs pNET cohort (NCT02358356) designed to test 12-month PFS 77% for PRRT+CAPTEM vs 60% for CAPTEM alone; planned pNET sample size 90; endpoints include PFS, ORR, OS, safety, and QoL (NCT02358356 chunk 1) Combination toxicity may be greater than single modality; mature comparative outcome data were not provided in extracted evidence (NCT02358356 chunk 1) Important ongoing/modern trial concept for intensification and sequencing in pNETs; not standard of care on the basis of extracted evidence alone (NCT02358356 chunk 1)
Newer TKIs: surufatinib Advanced NET/panNET after progression; availability varies by region ORR 19%; median PFS 10.9 vs 3.7 months; HR 0.34 (castillon2023seomgetneclinicalguidelines pages 9-10) TKI-related toxicity; regional access/regulatory heterogeneity; extracted evidence does not specify full AE profile here (castillon2023seomgetneclinicalguidelines pages 9-10) Increasingly discussed in contemporary sequencing reviews and real-world practice, especially where approved (castillon2023seomgetneclinicalguidelines pages 9-10)
Newer TKIs: lenvatinib Advanced progressive pancreatic NET in selected settings Response rate 44.2%; median PFS 15.6 months (castillon2023seomgetneclinicalguidelines pages 9-10) Evidence base less mature than everolimus/sunitinib; toxicity may limit broad uptake (castillon2023seomgetneclinicalguidelines pages 9-10) Considered an active newer antiangiogenic option, but integration into routine sequencing is still evolving (castillon2023seomgetneclinicalguidelines pages 9-10)
Newer TKIs: cabozantinib Progressive advanced NET, including pancreatic primaries, typically later-line / trial-informed use Phase II partial response rate ~15%; phase III CABINET ongoing/not fully reported in extracted evidence (castillon2023seomgetneclinicalguidelines pages 9-10) Evidence still emerging; toxicity and optimal placement in sequence remain under refinement (castillon2023seomgetneclinicalguidelines pages 9-10) Mentioned as an emerging option in recent guideline-oriented reviews rather than an established universal standard for NF-PanNET (castillon2023seomgetneclinicalguidelines pages 9-10)

Table: This table summarizes current management options for non-functional pancreatic neuroendocrine tumors, spanning observation, surgery, systemic therapy, PRRT, and newer targeted agents. It highlights where each approach fits clinically, the main efficacy numbers available from the extracted evidence, and the practical limitations relevant to real-world treatment sequencing.

Key efficacy statistics extracted from a 2023 guideline (SEOM‑GETNE; published May 2023; https://doi.org/10.1007/s12094-023-03205-6): - Sunitinib: median PFS 11.4 vs 5.5 months (HR 0.42; p<0.001) in advanced progressive panNETs (castillon2023seomgetneclinicalguidelines pages 9-10). - Everolimus: - RADIANT‑3: PFS 11.0 vs 4.6 months (HR 0.35). - RADIANT‑4: PFS 11.0 vs 3.9 months (HR 0.48). (castillon2023seomgetneclinicalguidelines pages 9-10). - CAPTEM (temozolomide+capecitabine): - E2211: PFS 22.7 vs 14.4 months vs temozolomide alone (HR 0.58; p=0.022), without OS benefit in the extracted summary. - SEQTOR: higher first-line response with chemotherapy vs everolimus (30% vs 11%) with similar first-line PFS (21.5 vs 23.6 months). (castillon2023seomgetneclinicalguidelines pages 9-10).

11.3 PRRT (177Lu‑DOTATATE): implementation and sequencing

A 2024 treatment sequencing review (published Oct 2024; https://doi.org/10.1007/s12254-024-01001-8) summarizes PRRT evidence and sequencing considerations: - NETTER‑1 showed major reduction in risk of progression/death (HR 0.21; median PFS not reached vs 8.4 months). - NETTER‑2 (first-line G2/G3) reported median PFS 22.8 vs 8.5 months; ORR 43% vs 9.3%. - Long-term hematologic toxicity (MDS/leukemia) occurs in ~3–4%. - Both SSA and PRRT require SSTR positivity, and placement in sequence depends on grade and tempo; ESMO places PRRT later for pancreatic NET after approved treatments (melhorn2024treatmentsequencingin pages 2-3, melhorn2024treatmentsequencingin pages 1-2).

11.4 Key ongoing / recent trials (ClinicalTrials.gov)

  • NeoLuPaNET (NCT04385992): Phase II single-arm trial of neoadjuvant 177Lu‑DOTATATE before surgery in resectable non-functioning PanNET at high recurrence risk; 31 enrolled; four cycles of 7,400 MBq every 6–8 weeks; primary endpoint 90‑day postoperative morbidity/mortality; completed (start 2020‑03‑09; completion 2023‑06‑26) (https://clinicaltrials.gov/study/NCT04385992) (NCT04385992 chunk 1).
  • CONTROL NETs (NCT02358356): Randomized phase II trial in pNET cohort comparing PRRT+CAPTEM vs CAPTEM alone; designed for 12‑month PFS 77% vs 60%; includes ORR, OS, safety, and QoL (EORTC QLQ‑C30; QLQ‑GINET21). PRRT regimen: 177Lu‑octreotate 7.8 GBq q8w ×4; CAPTEM dosing specified in protocol (https://clinicaltrials.gov/study/NCT02358356) (NCT02358356 chunk 1).

11.5 MAXO term suggestions (treatments)

(Informative mapping; requires ontology validation): - Active surveillance — MAXO:0000127 (clinical surveillance/monitoring) - Pancreatic tumor resection — MAXO:0001073 (surgical resection) - Somatostatin analog therapy — MAXO:0000766 - mTOR inhibitor therapy (everolimus) — MAXO:0000783 - Tyrosine kinase inhibitor therapy (sunitinib, others) — MAXO:0000784 - Peptide receptor radionuclide therapy — MAXO:0000945

12. Prevention

12.1 Primary prevention

No established primary prevention interventions were identified for sporadic NF‑PanNET in the retrieved evidence.

12.2 Secondary prevention: surveillance in hereditary syndromes

Hereditary syndrome reviews emphasize early detection via structured surveillance: - For MEN1, a 2024 review states mutation carriers should be in regular specialized screening programs and be managed in expert interdisciplinary centers; early diagnosis and individualized treatment can prolong expected lifespan (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3). - The hereditary syndromes review emphasizes genetic screening in childhood and diagnostic surveillance often in adolescence for asymptomatic carriers (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3).

13. Other species / natural disease

No evidence specific to naturally occurring pancreatic neuroendocrine tumors in non-human species was retrieved in this run. (A canine/human gallbladder neuroendocrine neoplasm review was retrieved but is anatomically distinct from pancreatic disease and was not used to avoid misclassification.)

14. Model organisms

No model organism papers (e.g., Men1 mouse models, RIP‑Tag models, organoids) were retrieved and extracted in the current evidence set; additional targeted searches in MGI/IMPC and PanNET model literature would be required.

15. Expert opinions and analysis (authoritative synthesis)

  • Diagnostic experts emphasize multimodal imaging and evolving roles for AI/radiomics and molecular assays, but note barriers such as reproducibility, standardization, and cost-effectiveness (battistella2024recentdevelopmentsin pages 20-26, battistella2024recentdevelopmentsin pages 1-6).
  • Sequencing experts stress individualized decision-making because of the growing number of active options; grade (Ki‑67), SSTR expression, and disease tempo are key determinants (melhorn2024treatmentsequencingin pages 2-3, melhorn2024treatmentsequencingin pages 1-2).

Notes on evidence gaps in this run

Several knowledge-base fields requested in the template (ICD‑10/ICD‑11 codes, MeSH terms, detailed AJCC/ENETS TNM staging tables, variant-level ClinVar classifications/allele frequencies, and model organism inventories) were not available from the retrieved evidence and would require additional database- and genetics-focused retrieval.

References

  1. (OpenTargets Search: pancreatic neuroendocrine tumor): Open Targets Query (pancreatic neuroendocrine tumor, 36 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (saleh2024pancreaticneuroendocrinetumors pages 1-2): Zena Saleh, Matthew Christopher Moccia, Zachary Ladd, Joneja Upasana, Yahui Li, Francis Spitz, Young Ki Hong, and Tao Gao. Pancreatic neuroendocrine tumors: signaling pathways and epigenetic regulation. International Journal of Molecular Sciences, Jan 2024. URL: https://doi.org/10.3390/ijms25021331, doi:10.3390/ijms25021331. This article has 17 citations.

  3. (battistella2024recentdevelopmentsin pages 1-6): Anna Battistella, Matteo Tacelli, Paola Mapelli, Marco Schiavo Lena, Valentina Andreasi, Luana Genova, Francesca Muffatti, Francesco De Cobelli, Stefano Partelli, and Massimo Falconi. Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms. Expert Review of Gastroenterology & Hepatology, 18:155-169, May 2024. URL: https://doi.org/10.1080/17474124.2024.2342837, doi:10.1080/17474124.2024.2342837. This article has 3 citations and is from a peer-reviewed journal.

  4. (sulciner2023surgicalmanagementof pages 10-11): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  5. (sulciner2023surgicalmanagementof pages 2-5): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  6. (castillon2023seomgetneclinicalguidelines pages 9-10): Jaume Capdevila Castillón, Teresa Alonso Gordoa, Alberto Carmona Bayonas, Ana Custodio Carretero, Rocío García-Carbonero, Enrique Grande Pulido, Paula Jiménez Fonseca, Angela Lamarca Lete, Angel Segura Huerta, and Javier Gallego Plazas. Seom-getne clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (nens) (2022). Clinical & Translational Oncology, 25:2692-2706, May 2023. URL: https://doi.org/10.1007/s12094-023-03205-6, doi:10.1007/s12094-023-03205-6. This article has 16 citations and is from a peer-reviewed journal.

  7. (melhorn2024treatmentsequencingin pages 2-3): Philipp Melhorn, Markus Raderer, and Barbara Kiesewetter. Treatment sequencing in gastroenteropancreatic neuroendocrine tumors. memo - Magazine of European Medical Oncology, 17:257-262, Oct 2024. URL: https://doi.org/10.1007/s12254-024-01001-8, doi:10.1007/s12254-024-01001-8. This article has 1 citations.

  8. (sulciner2023surgicalmanagementof pages 1-2): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  9. (battistella2024recentdevelopmentsin pages 16-20): Anna Battistella, Matteo Tacelli, Paola Mapelli, Marco Schiavo Lena, Valentina Andreasi, Luana Genova, Francesca Muffatti, Francesco De Cobelli, Stefano Partelli, and Massimo Falconi. Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms. Expert Review of Gastroenterology & Hepatology, 18:155-169, May 2024. URL: https://doi.org/10.1080/17474124.2024.2342837, doi:10.1080/17474124.2024.2342837. This article has 3 citations and is from a peer-reviewed journal.

  10. (castillon2023seomgetneclinicalguidelines pages 2-4): Jaume Capdevila Castillón, Teresa Alonso Gordoa, Alberto Carmona Bayonas, Ana Custodio Carretero, Rocío García-Carbonero, Enrique Grande Pulido, Paula Jiménez Fonseca, Angela Lamarca Lete, Angel Segura Huerta, and Javier Gallego Plazas. Seom-getne clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (nens) (2022). Clinical & Translational Oncology, 25:2692-2706, May 2023. URL: https://doi.org/10.1007/s12094-023-03205-6, doi:10.1007/s12094-023-03205-6. This article has 16 citations and is from a peer-reviewed journal.

  11. (papadopouloumarketou2024hereditarysyndromesassociated pages 1-3): Nektaria Papadopoulou-Marketou, Marina Tsoli, Eleftherios Chatzellis, Krystallenia I. Alexandraki, and Gregory Kaltsas. Hereditary syndromes associated with pancreatic and lung neuroendocrine tumors. Cancers, 16:2075, May 2024. URL: https://doi.org/10.3390/cancers16112075, doi:10.3390/cancers16112075. This article has 16 citations.

  12. (conzo2026pancreaticneuroendocrinetumors pages 2-4): Giovanni Conzo, Federico Maria Mongardini, Maddalena Paolicelli, Michele Klain, Giuseppe Bellastella, Alessandra Conzo, Zhou Bo, Eduardo Lanza, Leandra Piscopo, and Renato Patrone. Pancreatic neuroendocrine tumors: from benchside to surgical treatment. Medicina, 62:479, Mar 2026. URL: https://doi.org/10.3390/medicina62030479, doi:10.3390/medicina62030479. This article has 1 citations.

  13. (NCT02358356 chunk 1): Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study. Australasian Gastro-Intestinal Trials Group. 2015. ClinicalTrials.gov Identifier: NCT02358356

  14. (andersen2024welldifferentiatedg1and pages 1-2): Kirstine Øster Andersen, Sönke Detlefsen, Klaus Brusgaard, and Henrik Thybo Christesen. Well-differentiated g1 and g2 pancreatic neuroendocrine tumors: a meta-analysis of published expanded dna sequencing data. Frontiers in Endocrinology, May 2024. URL: https://doi.org/10.3389/fendo.2024.1351624, doi:10.3389/fendo.2024.1351624. This article has 10 citations.

  15. (maluchenko2024molecularbasisof pages 17-18): Alesia Maluchenko, Denis Maksimov, Zoia Antysheva, Julia Krupinova, Ekaterina Avsievich, Olga Glazova, Natalia Bodunova, Nikolay Karnaukhov, Ilia Feidorov, Diana Salimgereeva, Mark Voloshin, and Pavel Volchkov. Molecular basis of pancreatic neuroendocrine tumors. International Journal of Molecular Sciences, 25:11017, Oct 2024. URL: https://doi.org/10.3390/ijms252011017, doi:10.3390/ijms252011017. This article has 10 citations.

  16. (sulciner2023surgicalmanagementof media 0ba4a3b1): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  17. (sulciner2023surgicalmanagementof media 7d24a64d): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  18. (sulciner2023surgicalmanagementof media 210f90c9): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  19. (battistella2024recentdevelopmentsin pages 20-26): Anna Battistella, Matteo Tacelli, Paola Mapelli, Marco Schiavo Lena, Valentina Andreasi, Luana Genova, Francesca Muffatti, Francesco De Cobelli, Stefano Partelli, and Massimo Falconi. Recent developments in the diagnosis of pancreatic neuroendocrine neoplasms. Expert Review of Gastroenterology & Hepatology, 18:155-169, May 2024. URL: https://doi.org/10.1080/17474124.2024.2342837, doi:10.1080/17474124.2024.2342837. This article has 3 citations and is from a peer-reviewed journal.

  20. (conzo2026pancreaticneuroendocrinetumors pages 5-7): Giovanni Conzo, Federico Maria Mongardini, Maddalena Paolicelli, Michele Klain, Giuseppe Bellastella, Alessandra Conzo, Zhou Bo, Eduardo Lanza, Leandra Piscopo, and Renato Patrone. Pancreatic neuroendocrine tumors: from benchside to surgical treatment. Medicina, 62:479, Mar 2026. URL: https://doi.org/10.3390/medicina62030479, doi:10.3390/medicina62030479. This article has 1 citations.

  21. (sulciner2023surgicalmanagementof pages 15-16): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  22. (conzo2026pancreaticneuroendocrinetumors pages 13-13): Giovanni Conzo, Federico Maria Mongardini, Maddalena Paolicelli, Michele Klain, Giuseppe Bellastella, Alessandra Conzo, Zhou Bo, Eduardo Lanza, Leandra Piscopo, and Renato Patrone. Pancreatic neuroendocrine tumors: from benchside to surgical treatment. Medicina, 62:479, Mar 2026. URL: https://doi.org/10.3390/medicina62030479, doi:10.3390/medicina62030479. This article has 1 citations.

  23. (conzo2026pancreaticneuroendocrinetumors pages 10-11): Giovanni Conzo, Federico Maria Mongardini, Maddalena Paolicelli, Michele Klain, Giuseppe Bellastella, Alessandra Conzo, Zhou Bo, Eduardo Lanza, Leandra Piscopo, and Renato Patrone. Pancreatic neuroendocrine tumors: from benchside to surgical treatment. Medicina, 62:479, Mar 2026. URL: https://doi.org/10.3390/medicina62030479, doi:10.3390/medicina62030479. This article has 1 citations.

  24. (sulciner2023surgicalmanagementof pages 9-10): Megan L. Sulciner and Thomas E. Clancy. Surgical management of pancreatic neuroendocrine tumors. Cancers, 15:2006, Mar 2023. URL: https://doi.org/10.3390/cancers15072006, doi:10.3390/cancers15072006. This article has 46 citations.

  25. (melhorn2024treatmentsequencingin pages 1-2): Philipp Melhorn, Markus Raderer, and Barbara Kiesewetter. Treatment sequencing in gastroenteropancreatic neuroendocrine tumors. memo - Magazine of European Medical Oncology, 17:257-262, Oct 2024. URL: https://doi.org/10.1007/s12254-024-01001-8, doi:10.1007/s12254-024-01001-8. This article has 1 citations.

  26. (NCT04385992 chunk 1): Massimo Falconi. Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET. IRCCS San Raffaele. 2020. ClinicalTrials.gov Identifier: NCT04385992